Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials

Conclusions.
Baseline tumor volume is a significant prognostic factor in recurrent GBM. Clinical trial treatment arms must have a balanced distribution of tumor size, and tumor size should be considered when interpreting therapeutic efficacy.

Source: Neuro-Oncology - December 26, 2016 Category: Cancer & Oncology Authors: Ellingson, B. M., Harris, R. J., Woodworth, D. C., Leu, K., Zaw, O., Mason, W. P., Sahebjam, S., Abrey, L. E., Aftab, D. T., Schwab, G. M., Hessel, C., Lai, A., Nghiemphu, P. L., Pope, W. B., Wen, P. Y., Cloughesy, T. F. Tags: Clinical Investigations Source Type: research